Johnson & Johnson has reached a $5.5 billion settlement to resolve approximately 69,000 lawsuits alleging that its talc-containing baby powder caused ovarian cancer in U.S. consumers. The agreement, announced Monday, covers 99.75% of pending talc-related cases in American courts, marking one of the largest corporate settlements in corporate history.
Deal concludes decade-long litigation involving thousands of plaintiffs across federal and state jurisdictions.
The pharmaceutical company will cease all litigation related to talc-based products in the United States, bringing closure to claims dating back to its 1972 product launch. While J&J maintains scientific evidence disproves talc’s carcinogenic properties, the settlement avoids further legal exposure as it phases out talc use globally – discontinuing sales in the U.S. since 2020 and worldwide since 2023.
Health Authority Actions
The World Health Organization’s 2024 classification of talc as “probably carcinogenic to humans” intensified regulatory pressure, though J&J disputes these findings. The settlement includes compensation for plaintiffs diagnosed with ovarian cancer, mesothelioma, and related conditions linked to powder use.
Notable precedent includes the 2016 verdict where a St. Louis jury awarded $72 million to the Estate of Jacqueline Brady, later reduced and overturned. Subsequent cases have resulted in multi-million dollar awards, including recent $117 million and $165 million rulings in Missouri and Tennessee respectively.
J&J litigation executive Erik Haas stated the agreement “allows us to put this matter behind us,” while plaintiff attorneys described it as “fair resolution after years of exhaustive litigation.” The settlement excludes the UK’s ongoing £1 billion class action involving 7,000+ claimants, which was filed in October 2025 and currently under review by the High Court.